Association between CYP2E1 and NAT2 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis
SHENG Yun-jian
HE Hong-yan
Abstract：Objective To explore the potential association between cytochrome P4502E1 (CYP2E1) and N-acetyltransferase-2 (NAT2) polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity.Methods Medline/PubMed, EMBASE, Web of Science, and the Cochrane Library for the literatures about CYP2E1 polymorphism and anti-tuberculosis drug-induced hepatotoxicity were retrieved. All literatures were screened according to the inclusive and exclusive criteria, and the quality was measured. The efficacy was analyzed by odds ratios (OR) and 95％ confidence interval (CI) using Revman 5.0 software.Results A total of 9 literatures involving 2049 cases were included. Compared with thec1/c2 andc2/c2 genotypes, thec1/c1 genotype induced a higher risk of anti-tuberculosis drug-induced hepatotoxicity (OR=1.38, 95％CI: 1.08-1.77,P=0.01) for the PstI/RsaI polymorphism, and there was no significant difference for the DraI polymorphism (OR=0.78, 95％CI: 0.51-1.18,P=0.23). Compared with individuals with NAT2 fast or intermediate acetylator genotype andc1/c1 genotype, patients who were NAT2 slow acetylators and carried the high activity CYP2E1c1/c1 genotype had higher risk for anti-tuberculosis drug-induced hepatotoxicity (OR=3.10,P<0.0001).Conclusions CYP2E1c1/c1 genotype is a risk factor for anti-tuberculosis drug-induced hepatotoxicity, and the concomitant presence of slow acetylator NAT2 genotype may further increase this risk.
Keywords：CYP2E1polymorphismstuberculosisdrug-induced hepatotoxicitymeta-analysis
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 212-215 )